Navigation Links
Boehringer Ingelheim's investigational volasertib receives FDA Breakthrough Therapy designation
Date:9/17/2013

to advance Plk inhibitors into clinical development.

Volasertib is designed to inhibit the activity of Plk1, an enzyme in the Plk family that regulates cell division (mitosis).  This inhibition is intended to result in prolonged cell cycle arrest, ultimately leading to cell death (apoptosis).10

Volasertib* is not approved by the FDA; its safety and efficacy have not been established.

About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of pulmonary and cardiovascular medicine, metabolic disease, neurology, virology and immunology, Boehringer Ingelheim has embarked on a major research program to discover and develop innovative cancer treatments.  Working in close collaboration with the international scientific community and a number of the world's leading cancer centers, Boehringer Ingelheim's commitment to oncology is underpinned by using advances in science to develop a range of targeted therapies for various solid tumors and hematological cancers. The current focus of late-stage research includes compounds in three areas: signal transduction inhibition, angiogenesis inhibition and cell-cycle kinase inhibition. The company is also evaluating a robust and growing pipeline of early-stage oncology compounds in areas including growth/survival signaling, immunotherapy and epigenetics.

For information about participating in a Boehringer Ingelheim clinical trial, please visit www.bicancertrials.com or call 1.866.725.7110. Healthcare providers interested in learning more about Boehringer Ingelheim clinical trials in oncology can visit www.inoncologyus.com for additional information. 

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehri
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
2. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
3. Boehringer Ingelheim Announces Agreement to Study Real-World Use of Oral Anticoagulants
4. Boehringer Ingelheim Renews and Expands License to NextBio Research Platform
5. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies
6. Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference
7. Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
8. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
10. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
11. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... March 4, 2015  The strongest driver of ... the increasing elderly population, according to Kalorama Information. ... from the healthcare market research publisher, Global ... other risk factors such as obesity is contributing ... for innovative product designs and the trend toward ...
(Date:3/4/2015)... 4, 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that Pedro Lichtinger ... Opening Bell ® of the New York Stock ... trading as an NYSE MKT listed company on October ... is a trusted partner to Asterias Biotherapeutics, and we ...
(Date:3/4/2015)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... H. Burbank , Chief Executive Officer, will present at the ... on Wednesday, March 11 th at 3:50 ... be made available at http://ir.nxstage.com  at the time ... NxStage Medical, Inc. (Nasdaq: NXTM ) is a ...
Breaking Medicine Technology:Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3NxStage to Present at the Barclays Capital Global Healthcare Conference 2
(Date:3/4/2015)... New York, New York (PRWEB) March 04, 2015 ... ( http://www.lipitorlawsuitcenter.com/ ) that allege the statin drug caused ... forward in the U.S. District Court, District of South ... Conference will be convened on March 26, 2015 at ... have been directed to submit a Joint Status report ...
(Date:3/4/2015)... The ability of volumetric breast ... and help improve breast cancer risk prediction models ... presentation at the European Congress of Radiology (ECR) ... eight posters and 2 session presentations - highlight ... and quantitative breast imaging software tools to provide ...
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... reviewing the cardiovascular risks potentially associated with low testosterone ... Administration (FDA) announced that it will now require manufacturers ... increase their risk for heart attacks and strokes. In ... 2015, the agency also stated that it was requiring ...
(Date:3/4/2015)... 04, 2015 The print component of ... San Francisco Chronicle with a circulation of approximately 173,000 ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... Milorganite is composed of heat-dried microbes that have digested ...
(Date:3/4/2015)... March 04, 2015 The Global ... billion in 2014 and is estimated to grow ... of 4.0% from 2014 to 2019. , Browse ... Market for an analysis of industry trends, segments ... global liquefied petroleum gas market is classified into ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3
... Columbia University Medical Center are honing in on the development ... men. Tests of low doses of a compound that interferes ... dietary vitamin A, showed that it caused sterility in male ... antagonist were published in the June 1st issue of ...
... physical fitness levels between older adults who are ... and those who are members of a medically ... NiCole Keith, associate professor in the Department of ... she expected the study to show similar physical ...
... long been known that cancer cells eat a lot of sugar ... from using some sugar and a lot of oxygen, cancerous cells ... have been implicated in this process and now, reporting in the ... Hopkins University School of Medicine have discovered that this so-called Warburg ...
... News) -- Providing children with more toys to play with ... The new study also found that having more active toys ... particularly girls. In the study, led by ... New York, researchers offered three different quantities of toys to ...
... want to bounce back to their former vital selves as ... one of the largest survivor studies ever conducted shows ... fatigue, sleep, memory and concentration three to five years after ... prevalent these symptoms still are," said study co-investigator Lynne Wagner, ...
... A drug that targets a specific type of lung cancer ... people who take it. The drug, called crizotinib, has been ... largest group of patients to take it within the first ... meeting of the American Society of Clinical Oncology (ASCO). ...
Cached Medicine News:Health News:Could a birth control pill for men be on the horizon? 2Health News:Could a birth control pill for men be on the horizon? 3Health News:Indiana U. study points to health disparities in physical fitness 2Health News:Understanding cancer energetics 2Health News:Having More Toys May Boost Exercise Levels in Kids 2Health News:Cancer survivors can't shake pain, fatigue, insomnia, foggy brain 2Health News:Cancer survivors can't shake pain, fatigue, insomnia, foggy brain 3Health News:Benefit of targeted lung cancer therapy confirmed 2
... The XL Advantage delivers higher magnification ... a crisp, true image, even at the ... to edge clarity and precise color rendition ... treated with an anti-reflective coating produce a ...
... Keeler Prismatic loupes ... prismatic optics, guarenteeing edge ... precise colour rendition., ,Keeler ... aligned and treated with ...
... of doublet objective and high power negative ... 3.0x. The true benefit of this system ... focal clarity is made possible due to ... lightweight aluminum bar and individual interpupillary adjustment ...
... Made up of doublet objective and ... 2.0x, 2.5x and 3.0x. The true benefit ... Movement whilst maintaining focal clarity is made ... field. The ultra lightweight aluminum bar and ...
Medicine Products: